Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
Georg C LoddeFang ZhaoRudolf HerbstPatrick TerheydenJochen UtikalClaudia PföhlerJens UlrichAlexander KreuterPeter MohrRalf GutzmerFriedegund MeierEdgar DippelMichael WeichenthalPhilipp JansenBernd KowallWolfgang GaletzkaFabian HörstJens KleesiekBirte HellwigJörg RahnenführerLuisa RajcsanyiTriinu PetersAnke HinneyJan-Malte PlackeAntje SuckerAnnette PaschenJürgen C BeckerElisabeth LivingstoneLisa ZimmerAlpaslan TasdoganAlexander RoeschEva HadaschikDirk SchadendorfKlaus GriewankSelma UgurelPublished in: European journal of cancer (Oxford, England : 1990) (2024)
Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and survival.